Latest Breaking News On - Gastrointestinal oncology program - Page 1 : comparemela.com

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

Heinz josef lenzLos angelesAshling wahnerDepartment of medicineKeck school of medicineUniversity of southern californiaColorectal centerGastrointestinal oncology programDivision of oncologyDepartment of preventive medicineNorris comprehensive cancer centerClinical researchLive on airPreventive medicineSouthern californiaKeck school

Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRC

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Heinz josef lenzClinical researchDepartment of medicineGastrointestinal oncology programColorectal centerDivision of oncologyDepartment of preventive medicineKeck school of medicinePreventive medicineKeck schoolUsc norris comprehensive cancer centerOnclive tvColorectal cancer

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHolli kolkeyZeva wainbergTerry rosenYelenay janjigianMemorial sloan kettering cancer centerAmerican society of clinical oncologyArcus biosciences incGilead sciencesGastrointestinal oncology programCorporate communicationsChief gastrointestinal oncologyLead investigatorOncology programClinical oncologyAnnual meeting

Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Manisha shahSolid tumor serviceGastrointestinal oncology programWeill cornell medicineAdvanced digestive diseaseNewyork presbyterianKeynote 590 trialFrontline pembrolizumab plus chemotherapyPatients with esophageal cancer

All Eyes Are on IL-15 in Early Phase Studies

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

United statesNew jerseyMartine gutierrezGastrointestinal oncology programExchange commissionJohn theurer cancer centerImmunitybio incAmerican society of clinical oncology annual meetingYel researchGeorgetown lombardi cancer centerPhasei diseases groupDrug discovery phasei programMonitoring committeePhasei programHackensack meridian schoolProtocol review